Hims & Hers Expands Platform-Led Care with Diagnostics, Hormonal Health and At-Home Testing
Hims & Hers Health broadened its platform-led service by adding diagnostics, hormonal health and at-home testing to its provider-directed care offerings. This expansion provides patients with direct access to clinical assessments and personalized treatments, potentially enhancing user engagement and diversifying revenue streams.
1. Hims & Hers Outperforms Broader Market
In the latest trading session, shares of Hims & Hers Health, Inc. outpaced the S&P 500 by delivering a 2.05% gain, driven by higher-than-average volume of 4.8 million shares traded—30% above its 30-day daily average. Analysts at Jefferies noted that institutional buying increased by 12% over the past week, reflecting renewed confidence in the telehealth sector. The company’s market capitalization now stands just above $3.8 billion, positioning it as one of the top performers in the direct-to-consumer healthcare space this quarter.
2. Expansion of Provider-Directed Care Platform
Hims & Hers has rolled out three new at-home diagnostic tests—covering thyroid function, vitamin D levels and lipid panels—bringing its total portfolio to 12 tests available nationwide. In addition, the company launched a comprehensive hormonal health program for women in 15 states, including guided consultations with board-certified providers. Early adoption metrics indicate a 25% uptick in monthly active users for these services, with consumer surveys showing a 92% satisfaction rate. Management plans to add genetic screening options by Q3, aiming to leverage its subscription base of over 600,000 members to drive cross-sell opportunities.